Table 3.
PET/CT with different tracers and high-quality MRI to detect bone metastasis in PCa.
| Test | Absolute Sensitivity | Absolute Specificity | Diagnostic OR[Rank] | Superiority Index [Rank] | Relative Sensitivity | Relative Specificity | Datasets, n | Studies, n |
|---|---|---|---|---|---|---|---|---|
| 18F-NaF PET/CT | 0.95 (0.91–0.99) |
0.89 (0.84–0.94) |
256.89 (34.08–796.33) [4] |
1.08 (0.11–5.00) [4] |
1.00 (1.00–1.00) |
1.00 (1.00–1.00) |
10 | 9 |
| 18F-Choline PET/CT | 0.89 (0.84–0.94) |
0.91 (0.86–0.96) |
121.19 (22.43–355.84) [6] |
0.51 (0.09–3.00) [6] |
0.94 (0.87–1.01) |
1.03 (0.95–1.11) |
7 | 7 |
| 11C-Choline PET/CT | 0.86 (0.81–0.91) |
0.94 (0.89–0.99) |
212.63 (20.64–791.67) [5] |
0.75 (0.09–5.00) [5] |
0.91 (0.84–0.98) |
1.07 (0.98–1.16) |
7 | 7 |
| 68Ga-PSMA PET/CT | 0.91 (0.83–0.99) |
0.96 (0.87–1.05) |
4,633,299.15 (14.51–4,438,033.15) [1] |
4.56 (0.11–11.00) [1] |
0.96 (0.86–1.06) |
1.09 (0.96–1.22) |
5 | 5 |
| 3.0-T high-quality MRI | 0.94 (0.86–1.02) |
0.94 (0.86–1.02) |
6033.33 (27.09–39,719.47) [2] |
4.43 (0.14–11.00) [2] |
0.99 (0.89–1.09) |
1.07 (0.96–1.18) |
4 | 4 |
| 1.5-T high-quality MRI | 0.96 (0.90–1.02) |
0.90 (0.81–0.99) |
2,056.83 (23.96–11,589.08) [3] |
3.38 (0.11–9.00) [3] |
1.02 (0.93–1.11) |
1.02 (0.90–1.14) |
4 | 4 |
Data are reported as mean (range) unless otherwise indicated.
PET/CT, positron emission tomography/computed tomography; MRI, magnetic resonance imaging; PCa, Prostate cancer; NaF, Sodium fluoride; PSMA, Prostate membrane antigen; T, Tesla; CI credible interval; OR, odds ratio.
High-quality MRI was referred to the MRI equipped with multisequence, DWI used, and ≥2 imaging planes.